D-1253-2020 Class II Terminated

Recalled by Amneal Pharmaceuticals Of New York, LLC — Brookhaven, NY

FDA drug recall D-1253-2020 was initiated by Amneal Pharmaceuticals Of New York, LLC on Apr 15, 2020 and is designated Class II. Reason for recall: CGMP Deviations: potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA. The recall status is terminated (terminated Sep 8, 2021). Affected quantity: 11258 bottles.

Recall details

Product Type
Drugs
Report Date
May 6, 2020
Initiation Date
Apr 15, 2020
Termination Date
Sep 8, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
11258 bottles

Product description

Nizatidine Oral Solution, 15 mg/mL (75 mg/5mL) USP 480 mL bottles, Rx Only Distributed by: Gemini Laboratories, LLC Bridgewater, NJ 08807 NDC 60846-301-15

Reason for recall

CGMP Deviations: potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA.

Distribution pattern

Nationwide

Code information

06598004A 04/2020 06599001A 12/2020 06599002A 12/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1253-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1253-2020. Report a data issue: hello@regdatalab.com.